MAP2K7 and neoplasm: Lee et al. demonstrated synergistic effects of combination therapy with MEK inhibitor cobimetinib and immunotherapy for the treatment of KRAS-mutant NSCLC, showing anti-tumor effects and improved survival in a mouse model [38].